Related Experiment Video
Updated: Nov 28, 2025

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
Importance of Cullin4 Ubiquitin Ligase in Malignant Pleural Mesothelioma
Mayura Meerang1, Jessica Kreienbühl1, Vanessa Orlowski1
1Department of Thoracic Surgery, University Hospital Zürich, 8091 Zürich, Switzerland.
Abstract:
Neurofibromatosis type 2 (NF2), the tumor suppressor frequently lost in malignant pleural mesothelioma (MPM), suppresses tumorigenesis in part by inhibiting the Cullin4 ubiquitin ligase (CUL4) complex in the nucleus. Here, we evaluated the importance of CUL4 in MPM progression and tested the efficacy of cullin inhibition by pevonedistat, a small molecule inhibiting cullin neddylation. CUL4 paralogs (CUL4A and CUL4B) were upregulated in MPM tumor specimens compared to nonmalignant pleural tissues. High gene and protein expressions of CUL4B was associated with a worse progression-free survival of MPM patients. Among 13 MPM cell lines tested, five (38%) were highly sensitive to pevonedistat (half maximal inhibitory concentration of cell survival IC50 < 0.5 µM). This remained true in a 3D spheroid culture. Pevonedistat treatment caused the accumulation of CDT1 and p21 in both sensitive and resistant cell lines. However, the treatment induced S/G2 cell cycle arrest and DNA rereplication predominantly in the sensitive cell lines. In an in vivo mouse model, the pevonedistat treatment significantly prolonged the survival of mice bearing both sensitive and resistant MPM tumors. Pevonedistat treatment reduced growth in sensitive tumors but increased apoptosis in resistant tumors. The mechanism in the resistant tumor model may be mediated by reduced macrophage infiltration, resulting from the suppression of macrophage chemotactic cytokines, C-C motif chemokine ligand 2 (CCL2), expression in tumor cells.
Insights
Neurofibromatosis type 2 (NF2) loss in malignant pleural mesothelioma (MPM) upregulates Cullin4 (CUL4) ligase. Inhibiting CUL4 with pevonedistat shows therapeutic potential, prolonging survival in MPM mouse models.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Neurofibromatosis type 2 (NF2) loss is common in malignant pleural mesothelioma (MPM).
- The Cullin4 (CUL4) ubiquitin ligase complex is implicated in tumorigenesis and is a target of NF2.
- CUL4 activity is crucial for MPM progression.
Purpose of the Study:
- To investigate the role of CUL4 in MPM progression.
- To evaluate the efficacy of pevonedistat, a CUL4 neddylation inhibitor, in MPM treatment.
Main Methods:
- Analysis of CUL4A and CUL4B expression in MPM tissues and correlation with patient survival.
- Testing pevonedistat sensitivity in MPM cell lines and 3D spheroid cultures.
- In vivo studies using MPM mouse models to assess pevonedistat efficacy and mechanisms.
Main Results:
- CUL4A and CUL4B were upregulated in MPM tissues, with high CUL4B correlating to worse progression-free survival.
- 38% of tested MPM cell lines were sensitive to pevonedistat, showing cell cycle arrest and DNA rereplication.
- Pevonedistat prolonged survival in vivo, reduced tumor growth in sensitive models, and induced apoptosis in resistant models, potentially via CCL2-mediated macrophage suppression.
Conclusions:
- CUL4 upregulation is significant in MPM, and CUL4B expression predicts poor prognosis.
- Pevonedistat demonstrates therapeutic potential against MPM by targeting CUL4 neddylation.
- Pevonedistat exhibits efficacy in both sensitive and resistant MPM models, suggesting multifaceted therapeutic mechanisms.
More Related Videos
Related Concept Videos
Abnormal Proliferation
Induced Pluripotent Stem Cells
Somatic...
Anaphase Promoting Complex
Inhibition of Cdk Activity
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....

